Agilon Health, Inc. (NYSE:AGL) Receives Consensus Rating of "Hold" from Brokerages
Agilon Health, Inc. (NYSE:AGL - Get Free Report) has received an average recommendation of "Hold" from the fifteen research firms that are presently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and five
Agilon Health, Inc. (NYSE:AGL-Get Free Report) has received an average recommendation of "Hold" from the fifteen research firms that are presently covering the stock,Marketbeat Ratingsreports. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating on the company. The average 1-year target price among analysts that have covered the stock in the last year is $86. 1818. Several research firms have recently commented on AGL. Deutsche Bank Aktiengesellschaft upgraded Agilon Health from a "hold" rating to a "buy" rating and lifted their price objective for the stock from $33. 00 to $49. 00 in a report on Thursday, May 7th. Citigroup upgraded Agilon Health from a "sell" rating to a "neutral" rating and raised their price target for the stock from $105. 00 to $115. 00 in a research report on Monday, August 10th. Truist Financial set a $112. 00 price target on Agilon Health and gave the stock a "hold" rating in a research note on Thursday, August 6th. Jefferies Financial Group upgraded Agilon Health from a "hold" rating to a "buy" rating and boosted their price objective for the company from $27. 50 to $48. 00 in a research report on Thursday, May 7th. Finally, Wells Fargo & Company reissued an "overweight" rating and set a $146. 00 price objective (up from $141. 00) on shares of Agilon Health in a research note on Tuesday, August 11th. GetAgilon Healthalerts:View Our Latest Research Report on Agilon HealthInstitutional Trading of Agilon HealthA number of institutional investors have recently modified their holdings of the company. Goldman Sachs Group Inc. lifted its stake in Agilon Health by 196. 2% in the fourth quarter. Goldman Sachs Group Inc. now owns 20,055,214 shares of the company's stock worth $13,812,000 after acquiring an additional 13,283,930 shares during the period. AQR Capital Management LLC raised its holdings in Agilon Health by 1,346. 6% in the 4th quarter. AQR Capital Management LLC now owns 10,211,767 shares of the company's stock worth $7,033,000 after purchasing an additional 9,505,837 shares in the last quarter. North Peak Capital Management LLC raised its holdings in Agilon Health by 10. 8% in the 4th quarter. North Peak Capital Management LLC now owns 38,139,937 shares of the company's stock worth $26,267,000 after purchasing an additional 3,715,460 shares in the last quarter. Voleon Capital Management LP lifted its position in shares of Agilon Health by 5,519. 2% in the 3rd quarter. Voleon Capital Management LP now owns 2,741,039 shares of the company's stock worth $2,823,000 after purchasing an additional 2,692,259 shares during the period. Finally, UBS Group AG boosted its stake in shares of Agilon Health by 250. 7% during the 4th quarter. UBS Group AG now owns 3,395,366 shares of the company's stock valued at $2,339,000 after purchasing an additional 2,427,136 shares in the last quarter. Agilon Health Price PerformanceShares ofAgilon Health stockopened at $96. 62 on Monday. Agilon Health has a 52-week low of $7. 48 and a 52-week high of $133. 04. The stock has a market capitalization of $1. 62 billion, a price-to-earnings ratio of -6. 77 and a beta of 3. 01. The company has a fifty day moving average of $106. 88 and a 200-day moving average of $58. 56. The company has a debt-to-equity ratio of 0. 07, a quick ratio of 1. 08 and a current ratio of 1. 08. Agilon Health (NYSE:AGL-Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported $1. 04 EPS for the quarter, topping analysts' consensus estimates of $0. 14 by $0. 90. The company had revenue of $1. 49 billion for the quarter, compared to analysts' expectations of $1. 45 billion. Agilon Health had a negative net margin of 3. 92% and a negative return on equity of 119. 38%. Equities research analysts expect that Agilon Health will post -2. 95 EPS for the current year. Agilon Health Company Profile(Get Free Report)Agilon HealthNYSE: AGLis a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery. Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs. Recommended StoriesFive stocks we like better than Agilon HealthThe Metals Company’s Big Bet Now Comes Down to a LicenseOneSpaWorld Keeps Turning Cruise Demand Into Record EarningsMeta and Tesla Are Rebounding From Oversold Levels—Now What?AMG’s Alternatives Boom Powers Record GrowthThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat. com. Continue following MarketBeatAdd MarketBeat as your preferred source on Google to see our latest stories in your feed. Should You Invest $1,000 in Agilon Health Right Now?Before you consider Agilon Health, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified thefive stocksthat top analysts are quietly whispering to their clients to buy now before the broader market catches on. . . and Agilon Health wasn't on the list. While Agilon Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks HereEnter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report